Coronavirus Update: Two Treatments Progress As Moderna/Takeda Investigation Concludes
Executive Summary
Takeda and Moderna have identified the source of metallic particles in some lots of mRNA-1273 in Japan, but believe the two deaths identified to be coincidental. Pfizer starts protease inhibitor trial, and Rigel reports fostamatinib data.
You may also be interested in...
Stock Watch: How The Pandemic Impact On Pharma’s Value Chain Is Mutating
From clinical trials to in-person sales calls, the pharmaceutical value chain has been tested by the COVID-19 pandemic, but has held up. Nevertheless, recent friction within this chain may be more than a passing irritation.
Coronavirus Update: Another Post-Moderna Vaccine Death Reported In Japan
A third death has been reported in Japan following dosing with Moderna's mRNA vaccine and while an investigation is underway, it is not seen as product-related. Takeda has also signed a production and supply deal with Japan's government for Novavax's nanoparticle vaccine.
Coronavirus Update: Japan Probes Deaths After Moderna Vaccine
Government and companies conducting urgent investigation into two deaths in recipients of Moderna vaccine, the causes of which remain unclear at this stage.